Condition · ICD-10 M81.0

Osteoporosis

Bone Density Loss

A condition of decreased bone density and strength that increases fracture risk, particularly in the hip, spine, and wrist.

Osteoporosis affects approximately 10 million Americans, with millions more having low bone mass (osteopenia). It is most prevalent in postmenopausal women due to estrogen deficiency accelerating bone resorption. Bisphosphonates are the first-line pharmacologic treatment, significantly reducing fracture risk. Adequate calcium and vitamin D intake are foundational to prevention and treatment.

At a glance
Medications tracked
6
First-line options
Alendronate, Risedronate
Related conditions
MenopauseHypothyroidismRheumatoid ArthritisHyperlipidemia

First-line Related Treatments

Commonly associated primary options — verify with your clinician

Primary options
Alendronate
Alendronate
Rx
Tablet
Strength 10 mg
NDC 64980-340-01
Risedronate
Risedronate
Rx
Tablet
Strength 150 mg
NDC 65862-870-11

Short-term / As-needed

Related options for acute or bridging use

Acute or bridging use
Calcium Carbonate
Calcium Carbonate
OTC
Tablet
Strength 1000 mg
NDC 0135-0118-01
Calcium Carbonate
Calcium Carbonate
OTC
Capsule
Strength 55 mg/500mg
NDC 84540-303-01

Situational

Related options for specific presentations

Specific presentations
Raloxifene
Raloxifene
Rx
Tablet
Strength 60 mg
NDC 60687-266-21
Teriparatide
Teriparatide
Rx
Tablet
Strength 20 mcg
NDC 0002-8400-01

Top treatments tried for Osteoporosis

Community-driven data · early preview

Alendronate
1,800 people tried
4.3
Risedronate
1,520 people tried
4.1
Calcium Carbonate
1,240 people tried
4.0
Calcium Carbonate
960 people tried
3.8
Help build the dataset — log treatments you've tried, rate what helped, and report side effects.